Bovie Medical Corporation is actively engaged in the business of manufacturing and marketing a variety of electrosurgical medical products as well as developing related technologies and products. Recently, greater effort and resources have been directed towards manufacturing electrosurgical generators which are primarily used for outpatient surgical procedures. Bovie continues the ongoing development of high-powered generators for operating room use. It is estimated that the electrosurgery industry is currently growing 10% annually and is used in 80% of all surgical procedures performed worldwide.
 

	John Aneralla Buttonwood Advisory Group, Inc. 15705 Framingham Lane Huntersville, NC 28078 Toll Free Phone: (800) 940-9087
	Bovie Medical Corporation Annouces Second Quarter and Six Month Financial Results; Secures $5 Million Line of Credit Commitment from RBC Centura Bank August 13, 2008   Bovie Medical Corporation Annouces FDA Clearance for Sale and Marketing of its MEG Laparoscopic Line; Submits 510(k) Application for Icon GP Generator August 5, 2008   Bovie Medical Corporation Announces Market Release of Canady APC Probes; FDA Submission of MEG Laparoscopic Instrument Line June 3, 2008   Bovie Medical Corporation Announces First Quarter Financial Results May 14, 2008   Bovie Medical Corporation Announces CE Mark For Sale And Marketing Of MEG Laparoscopic Line May 5, 2008   More news releases
	To Be Announced   Upcoming events
	See more about Bovie Corp. stock

• Filed CE mark for sale and marketing of the Modular Ergonomic Instruments (MEG Laparoscopic line), allowing the MEG Laparoscopic line to be marketed throughout the European Union.
  

• Acquired technology, patents, and assets related to the use of conductive sintered steel as an electrode for radio frequency (RF) cutting and coagulation, intended to lower blood loss, quicken procedure times and provide cost savings for hospitals.

• First quarter net income was $.01 per diluted share on revenues of $6,677,567.

• 2007 revenues increased to a record $28.7 million. Net income for the year was $2,400,591 or $.14 per diluted share. The Company recognized a provision for income taxes of approximately $871,000 during the year.

• October 2007 named to Forbes list of America’s 200 Best Small Cap Companies (#128).

• May 2007 acquired remaining 50% interest in J-Plasma – The technology utilizes a gas ionization process allowing the surgeon to control temperatures and intensities, resulting in precision, minimal invasiveness and an absence of conductive currents during a medical procedure.

• May 2007 launched the initial marketing of the Company’s ICON GI device. The product design and styling adds a new dimension to Bovie’s continued expansive array of generators. Additionally, the product is expected to be the basis for entry into other niche markets.

• Completed the initial development of the Company’s patent pending Polarian line of monopolar and bipolar modular forceps. The Polarian line allows the Company to gain entree into bipolar vessel sealing and coagulation, which is one of the fastest growing markets in Endoscopy.

The Company’s products compete primarily in the multi-billion dollar market for electrosurgical generators and single-use specialty medical products. Electrosurgery products are used in approximately 80% of all surgical procedures. Industry demand for electrosurgical medical products is being favorably impacted by several trends including: the aging population, increased emphasis on less invasive surgical procedures, higher level of outpatient care, continuing pressure to improve productivity and reduce costs; and the heightened awareness for reducing the transmission of infectious diseases.
 
ICON GI - Approximate Worldwide Market For GI Generators, Argon Plasma Generators and Accessories $150 million
The ICON GI was designed in collaboration with GI physicians and nurses and offers many new features including digital output, a touch screen interface, physician preference database, neutral electrode monitoring, and common sense messages. The ICON platform provides the basis to develop customized generators for other specialties.
 
Standard Electrosurgical Generators & Accessories
Standard electrosurgical generators range in power from 30-300 watts and are used in physician offices, surgery centers and hospitals. Bovie holds a dominate market position in physician offices for these products and a growing market share in surgery centers and hospitals.
 
Battery Operated Cauteries
Battery operated cauteries represent the Company's original line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The Company estimates it manufactures more types of cauteries than any other company in the world controlling up to 70% of the market, including a line of replaceable battery and tip cauteries, which are popular in overseas markets.
 

Polarian Vessel Sealing Instruments - Approximate worldwide market $500 million
The patent pending Polarian line of forceps allows for monopolar and bipolar energy combined with intelligent feedback from an electrosurgical generator. The Polarian handle will accommodate a wide array of possible applications in either monopolar or bipolar surgeries serving the endoscopic needs. The Endoscopy market is the fastest growing market in electrosurgery. The Polarian line of instruments are subject to 510k FDA clearance to market.

Modular Ergonomic Instruments (MEG Line) - Approximate worldwide market $200 million arthroscopic/ $300 million laparoscopic
The patent pending advanced modular forceps come with light metallic grips, transparent ratchet and ergonomic design, which is expected to reduce surgeon fatigue and improve tactile feel. The MEG family of forceps combined with Bovie’s electrosurgical generators offers users cost savings through simplified inventory management.

ICON GS Plasma System and related products - Approximate total worldwide market exceeds $1 billion
The technology utilizes a gas ionization process producing a stable thin beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon great precision, minimal invasiveness and an absence of conductive currents during surgery. Potential markets include gynecology, urology, dermatology, plastic surgery, neurology, gastroenterology, and veterinary medicine. Bovie anticipates directing its resources to each individual niche as best suited to the Company's overall business plan. J-Plasma and related products are subject to 510k FDA clearance to market.

 This corporate information sheet is intended to provide general information about the Company. It is not designed to be a source for making investment decisions, and Bovie will make every reasonable effort to include accurate and current information. Except for the historical information contained herein, this information may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company's SEC filings. Neither Bovie Medical Corporation nor any party involved in creating, producing or delivering this information sheet shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user's access, use, or liability to use the corporate information sheet, or any errors or omissions in the content.